AMBULATORY INFUSION  ·  SPECIALTY PHARMACY  ·  THERAPY MANAGEMENT
Home  /  Therapy Areas  /  Rheumatology and Autoimmune Disease
Therapy Area

Rheumatology and Autoimmune Disease.

Conditions we treat

  • Rheumatoid arthritis (RA)
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Systemic lupus erythematosus (SLE)
  • Juvenile idiopathic arthritis
  • Sjögren’s syndrome
  • Vasculitis (granulomatosis with polyangiitis, microscopic polyangiitis)
  • Adult-onset Still’s disease

Advanced rheumatologic and autoimmune therapies we deliver

TheraVite Health delivers and manages complex rheumatologic and autoimmune biologics, including high-cost therapies administered via infusion, subcutaneous injection, and specialty pharmacy dispensing.

Infusion therapies (in-suite administration)

  • Remicade (infliximab) and biosimilars — IV anti-TNF biologic
  • Rituxan (rituximab) — IV anti-CD20, also used in vasculitis
  • Orencia (abatacept) — IV T-cell co-stimulation modulator
  • Actemra (tocilizumab) — IV IL-6 receptor antagonist

Subcutaneous therapies (specialty pharmacy dispensing)

  • Humira (adalimumab) and biosimilars — SC anti-TNF
  • Enbrel (etanercept) — SC TNF receptor fusion protein
  • Cimzia (certolizumab pegol) — SC anti-TNF
  • Cosentyx (secukinumab) — SC IL-17A inhibitor
  • Skyrizi (risankizumab) — SC IL-23 inhibitor
  • Tremfya (guselkumab) — SC IL-23 inhibitor
  • Orencia (abatacept) — SC formulation, weekly self-injection
  • Actemra (tocilizumab) — SC formulation
TheraVite supports both administration (infusion) and dispensing (specialty pharmacy), enabling seamless transitions between IV induction and self-administered maintenance therapy.

What makes TheraVite’s approach distinct

Rheumatology patients often require coordination across multiple specialty drugs and biosimilar transitions over the course of long-term therapy. TheraVite’s integrated infusion-plus-pharmacy model is particularly well-suited to RA and psoriatic arthritis patients, who frequently transition between IV biologics (Remicade, Orencia IV) and at-home SC therapies (Humira, Enbrel, Cosentyx) over time. Your dedicated multidisciplinary care team handles the prior authorization and clinical transition without requiring you to switch pharmacy providers.

For referring providers

TheraVite handles prior authorization, benefits investigation, and payor credentialing for all therapies listed above. For drugs subject to limited distribution networks, we are pursuing manufacturer access in parallel with URAC accreditation. Contact us for current access status by drug.

Submit a referral →

For patients

If you have been prescribed any of the therapies above, TheraVite can typically begin treatment within 5 to 10 business days of receiving your prescription. We handle insurance verification, prior authorization, and patient onboarding so you can focus on your therapy.

Schedule an appointment →

Ready to get started?

Refer a Patient Schedule an Appointment